Navigation Links
Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
Date:2/17/2011

FRANKLIN, Mass., Feb. 17, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that development of the commercially ready Symphony tCGM System is ahead of schedule.  The company said that the system will be ready for demonstration in the second quarter and it will be used in a clinical trial shortly thereafter, replacing the prototype used in earlier clinical trials.  

Echo said it anticipates that upon completion of the development work no further changes will be made to the Symphony tCGM System, and that the device will be the one used for sale, subject to positive clinical studies and FDA market clearance of the product.  The addressable market for needle-free, continuous wireless glucose monitoring in the hospital critical care setting exceeds $1 billion annually and the global glucose monitoring market exceeds $12 billion annually.

"With the successful completion of our recent financing we now have sufficient capital to accelerate the product development work of our Symphony tCGM System," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We are now prepared to complete our final development work and clinical validation.  This next generation Symphony device incorporates substantial improvements beyond the prototype used in earlier studies and we look forward to validating those improvements in clinical testing."  

The Symphony tCGM System incorporates Echo's proprietary Prelude SkinPrep System, with a noninvasive wireless biosensor and a wireless monitor or handheld device for needle-free, continuous monitoring of glucose levels.  

About Echo TherapeuticsEc
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
3. Echo Therapeutics Announces Appointments to Board of Directors
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
6. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
7. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
8. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
9. NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
10. DSM and NKT Therapeutics Sign Contract for Lead Product Development and Manufacture
11. JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... , October 22, 2014 ... Disposable Gloves Market (Product type, Form, End user, Application ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, ... disposable gloves market. Based on key trends tracked, it ... valued at $7.9 billion by 2020, registering a CAGR ...
(Date:10/22/2014)... 22, 2014  With a vision to ensure ... a Global Pharmaceutical and Biotech manufacturer selects and ... turnkey solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... and aggregated by the Xyntek and Antares solution ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2
... , , ... Inc. (Nasdaq: ALXA ) today announced preliminary results from ... in patients with migraine headache. Both AZ-104 dose groups trended ... endpoint, which was defined as pain-relief at the 2-hour time point, ...
... SAN FRANCISCO, Sept. 14 Schering-Plough Corporation (NYSE: ... vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, ... treatment-experienced HIV-infected patients. The results showed that vicriviroc ... increased CD4 cell counts, and was generally well tolerated ...
Cached Medicine Technology:Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 2Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 3Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 4Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 5Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 2Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 3Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 4Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 5
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ... develops novel drug targets that disrupt the advance ... Dr. Anders Boegh Jensen to its Scientific Advisory ... his considerable expertise in biotechnology and molecular biology ...
... to better treatment decisions for respiratory infections, experts say , ... may be able to help doctors determine which patients need ... in the Sept. 9 issue of the Journal of ... test resulted in less antibiotic use. , If the protocol ...
... , NEW BRUNSWICK, N.J., Sept. 8 Johnson ... Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15th, at ... Surgical Care for Johnson & Johnson, will represent the Company in ... This broadcast will be available to interested investors and ...
... , , LOS ... Dr. Christina Restrepo has achieved diplomate status with the American College ... Restrepo graduated in 2003 from the University of Florida College of ... small animal medicine and surgery at the renowned Animal Medical Center ...
... , RANCHO CORDOVA, Calif., Sept. 8 ThermoGenesis ... that process and store adult stem cells, announced today it will report ... ended June 30, 2009, on Wednesday, September 9, 2009. , , ... Management will host a conference call Wednesday, September 9, 2009 at 2:00 ...
... , , ... Chemistry September 15 at UC Berkeley Campus , , ... hazardous chemicals in the air and water have led scientists to ... troubling health effects are associated with endocrine disrupting chemicals (EDCs) that ...
Cached Medicine News:Health News:GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board 2Health News:Blood Test Narrows Down Need for Antibiotics 2Health News:Blood Test Narrows Down Need for Antibiotics 3Health News:Animal Dermatology Clinic Marina del Rey Announces Dr. Christina Restrepo, DVM Achieves Diplomate Status With the American College of Veterinary Dermatology 2Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 2Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 3Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 4Health News:Inventor of Green Catalysts Offers Solutions for Cleaning Toxins and Pollutants in the Environment 2
Intact PTH EIA Bone and Mineral Metabolism 021-SDX016 Parathyroid Hormone...
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
... Immunoscan MPO-ANCA Kit is an enzyme immunoassay ... in human serum of the subclass of ... to be used as an aid in ... family of autoantibodies associated with vasculitic disorders ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: